Form 4: Tandem Diabetes Officer Reports Future RSU Vesting
Statement of Changes in Beneficial Ownership
Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark Novara, reported a future vesting of 7,415 restricted stock units and subsequent tax withholding on December 15, 2025.
Summary
- Mark David Novara, Executive Vice President & Chief Commercial Officer of Tandem Diabetes Care Inc. (TNDM), reported a transaction scheduled for December 15, 2025.
- The transaction involves the vesting of 7,415 restricted stock units (RSUs) into common stock.
- Concurrently, 3,843 shares of common stock will be disposed of to satisfy tax withholding requirements at a price of $22.11 per share.
- Following these transactions, Novara will beneficially own 35,956 shares of common stock directly.
- Novara will also beneficially own 29,658 derivative securities (unvested RSUs) directly.
- The reported transaction is made pursuant to a Rule 10b5-1 pre-planned contract for the purchase or sale of equity securities.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned executive compensation event (RSU vesting and tax withholding). This is a neutral event, neither significantly positive nor negative for the company's operational or financial outlook.
Positives
- The vesting of restricted stock units indicates continued equity compensation for a key executive, aligning management's interests with shareholders.
- The transaction is part of a pre-planned Rule 10b5-1 plan, demonstrating structured and transparent insider trading practices.
Negatives
- A portion of the vested shares (3,843 shares) was withheld to cover tax obligations, resulting in a reduction of direct common stock ownership.
Future Outlook
The remaining unvested Restricted Stock Units (29,658 units) are scheduled to vest in eight equal quarterly installments following the initial 33% vesting on December 15, 2024.
Industry Context
This filing is a routine disclosure of an insider's equity transaction, specifically related to executive compensation. It does not provide information on broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Reference | The Restricted Stock Units were awarded pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended. | 12/15/2023 | Reinforces the company's established executive compensation framework and long-term incentive alignment. |
Stakeholder Impact
- Shareholders: Minor impact, as it's a routine compensation event for an executive, reflecting standard equity dilution from RSU vesting.
- Employees: Demonstrates the company's ongoing use of equity-based compensation to incentivize key personnel.
Next Steps
- Future quarterly vesting installments of the remaining 29,658 Restricted Stock Units.
Key Dates
| Date | Description |
|---|---|
| 12/15/2023 | Date Restricted Stock Units (RSUs) were awarded pursuant to the 2023 Long-Term Incentive Plan. |
| 12/15/2024 | Date of the first vesting event for the RSUs, where thirty-three percent (33%) of the total shares vested. |
| 12/15/2025 | Date of the reported transaction, involving RSU vesting and tax withholding. |
| 12/17/2025 | Date the Form 4 filing was signed. |
Keywords
Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Tax Withholding, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.